Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:enzacamene
go back to main search page
Accession:CHEBI:135937 term browser browse the term
Synonyms:related_synonym: 4-Methylbenzylidenecamphor;   Formula=C18H22O;   InChI=1S/C18H22O/c1-12-5-7-13(8-6-12)11-14-15-9-10-18(4,16(14)19)17(15,2)3/h5-8,11,15H,9-10H2,1-4H3/b14-11+;   InChIKey=HEOCBCNFKCOKBX-SDNWHVSQSA-N;   SMILES=C\\1(C2(CCC(/C1=C\\C=3C=CC(=CC3)C)([H])C2(C)C)C)=O;   methylbenzylidenecam;   p-Methylbenzylidenecamphor
 xref: CAS:36861-47-9;   Drug_Central:4292
 xref_mesh: MESH:C038939


show annotations for term's descendants           Sort by:
enzacamene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABAT 4-aminobutyrate aminotransferase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ABAT mRNA CTD PMID:25607892 NCBI chr16:8,674,617...8,784,570
Ensembl chr16:8,674,596...8,784,575 		JBrowse link
G ACTN1 actinin alpha 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ACTN1 mRNA CTD PMID:25607892 NCBI chr14:68,874,128...68,979,302
Ensembl chr14:68,874,128...68,979,440 		JBrowse link
G ADAM17 ADAM metallopeptidase domain 17 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA CTD PMID:25607892 NCBI chr 2:9,488,486...9,555,830
Ensembl chr 2:9,488,486...9,556,732 		JBrowse link
G ADGRG1 adhesion G protein-coupled receptor G1 multiple interactions
increases expression		 EXP ADGRG1 mRNA inhibits the reaction [enzacamene results in decreased expression of TGM2 mRNA]; ADGRG1 mRNA promotes the reaction [enzacamene results in increased expression of CCL17 mRNA]
enzacamene results in increased expression of ADGRG1 mRNA		 CTD PMID:30597193 NCBI chr16:57,619,738...57,665,567
Ensembl chr16:57,610,652...57,665,580 		JBrowse link
G AR androgen receptor multiple interactions EXP enzacamene binds to and results in decreased activity of AR protein; enzacamene inhibits the reaction [Metribolone binds to and results in increased activity of AR protein] CTD PMID:15537743 PMID:24004914 NCBI chr  X:67,544,021...67,730,619
Ensembl chr  X:67,544,021...67,730,619 		JBrowse link
G AVP arginine vasopressin multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of AVP mRNA CTD PMID:34383603 NCBI chr20:3,082,556...3,084,724
Ensembl chr20:3,082,556...3,084,724 		JBrowse link
G BDNF brain derived neurotrophic factor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of BDNF mRNA CTD PMID:25607892 NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058 		JBrowse link
G BGLAP bone gamma-carboxyglutamate protein increases expression ISO enzacamene results in increased expression of BGLAP protein CTD PMID:15979666 NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317 		JBrowse link
G BSN bassoon presynaptic cytomatrix protein multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of BSN mRNA CTD PMID:25607892 NCBI chr 3:49,554,477...49,673,130
Ensembl chr 3:49,554,477...49,671,549 		JBrowse link
G CACNA1A calcium voltage-gated channel subunit alpha1 A multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1A mRNA CTD PMID:25607892 NCBI chr19:13,206,442...13,506,479
Ensembl chr19:13,206,442...13,633,025 		JBrowse link
G CACNA1C calcium voltage-gated channel subunit alpha1 C multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA1C mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1C mRNA CTD PMID:25607892 NCBI chr12:1,970,780...2,697,950
Ensembl chr12:1,970,772...2,697,950 		JBrowse link
G CACNA1D calcium voltage-gated channel subunit alpha1 D multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA1D mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1D mRNA CTD PMID:25607892 NCBI chr 3:53,494,611...53,813,733
Ensembl chr 3:53,328,963...53,813,733 		JBrowse link
G CACNA1E calcium voltage-gated channel subunit alpha1 E multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1E mRNA CTD PMID:25607892 NCBI chr 1:181,317,699...181,808,084
Ensembl chr 1:181,317,690...181,813,262 		JBrowse link
G CACNA1F calcium voltage-gated channel subunit alpha1 F multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1F mRNA CTD PMID:25607892 NCBI chr  X:49,205,063...49,233,340
Ensembl chr  X:49,205,063...49,233,371 		JBrowse link
G CACNA1G calcium voltage-gated channel subunit alpha1 G multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNA1G mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1G mRNA CTD PMID:25607892 NCBI chr17:50,560,715...50,627,474
Ensembl chr17:50,560,715...50,627,474 		JBrowse link
G CACNA1H calcium voltage-gated channel subunit alpha1 H multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1H mRNA CTD PMID:25607892 NCBI chr16:1,153,106...1,221,768
Ensembl chr16:1,153,103...1,224,169 		JBrowse link
G CACNA1I calcium voltage-gated channel subunit alpha1 I multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNA1I mRNA CTD PMID:25607892 NCBI chr22:39,570,753...39,689,735
Ensembl chr22:39,570,753...39,689,735 		JBrowse link
G CACNA2D1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA2D1 mRNA CTD PMID:25607892 NCBI chr 7:81,946,444...82,443,956
Ensembl chr 7:81,946,444...82,443,956 		JBrowse link
G CACNA2D2 calcium voltage-gated channel auxiliary subunit alpha2delta 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D2 mRNA CTD PMID:25607892 NCBI chr 3:50,362,613...50,504,244
Ensembl chr 3:50,362,613...50,504,244 		JBrowse link
G CACNA2D3 calcium voltage-gated channel auxiliary subunit alpha2delta 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA2D3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D3 mRNA CTD PMID:25607892 NCBI chr 3:54,122,552...55,074,557
Ensembl chr 3:54,122,552...55,074,557 		JBrowse link
G CACNB1 calcium voltage-gated channel auxiliary subunit beta 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB1 mRNA CTD PMID:25607892 NCBI chr17:39,173,453...39,197,669
Ensembl chr17:39,173,453...39,197,702 		JBrowse link
G CACNB2 calcium voltage-gated channel auxiliary subunit beta 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA CTD PMID:25607892 NCBI chr10:18,140,424...18,543,557
Ensembl chr10:18,140,424...18,543,557 		JBrowse link
G CACNB3 calcium voltage-gated channel auxiliary subunit beta 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNB3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB3 mRNA CTD PMID:25607892 NCBI chr12:48,814,480...48,828,941
Ensembl chr12:48,813,794...48,828,941 		JBrowse link
G CACNG2 calcium voltage-gated channel auxiliary subunit gamma 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNG2 mRNA CTD PMID:25607892 NCBI chr22:36,560,857...36,703,752
Ensembl chr22:36,560,857...36,703,752 		JBrowse link
G CACNG5 calcium voltage-gated channel auxiliary subunit gamma 5 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG5 mRNA CTD PMID:25607892 NCBI chr17:66,835,117...66,894,751
Ensembl chr17:66,835,117...66,894,751 		JBrowse link
G CACNG6 calcium voltage-gated channel auxiliary subunit gamma 6 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNG6 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG6 mRNA CTD PMID:25607892 NCBI chr19:53,991,149...54,012,666
Ensembl chr19:53,991,637...54,012,666 		JBrowse link
G CACNG8 calcium voltage-gated channel auxiliary subunit gamma 8 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG8 mRNA CTD PMID:25607892 NCBI chr19:53,962,937...53,990,215
Ensembl chr19:53,962,937...53,990,215 		JBrowse link
G CAMK2B calcium/calmodulin dependent protein kinase II beta multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CAMK2B mRNA CTD PMID:25607892 NCBI chr 7:44,217,154...44,326,013
Ensembl chr 7:44,210,019...44,334,577 		JBrowse link
G CARTPT CART prepropeptide multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in increased expression of CARTPT mRNA CTD PMID:34383603 NCBI chr 5:71,719,275...71,721,045
Ensembl chr 5:71,719,275...71,721,048 		JBrowse link
G CASK calcium/calmodulin dependent serine protein kinase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CASK mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CASK mRNA CTD PMID:25607892 NCBI chr  X:41,514,934...41,923,554
Ensembl chr  X:41,514,934...41,923,554 		JBrowse link
G CCL17 C-C motif chemokine ligand 17 multiple interactions
increases expression		 EXP ADGRG1 mRNA promotes the reaction [enzacamene results in increased expression of CCL17 mRNA] CTD PMID:30597193 NCBI chr16:57,396,093...57,416,063
Ensembl chr16:57,404,767...57,416,063 		JBrowse link
G CCL2 C-C motif chemokine ligand 2 increases expression EXP enzacamene results in increased expression of CCL2 mRNA CTD PMID:23397585 NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208 		JBrowse link
G CD44 CD44 molecule (IN blood group) multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CD44 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CD44 mRNA CTD PMID:25607892 NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402 		JBrowse link
G CHRDL1 chordin like 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CHRDL1 mRNA CTD PMID:25607892 NCBI chr  X:110,673,856...110,795,817
Ensembl chr  X:110,673,856...110,795,819 		JBrowse link
G CNST consortin, connexin sorting protein increases expression EXP enzacamene results in increased expression of CNST mRNA CTD PMID:23397585 NCBI chr 1:246,566,456...246,668,595
Ensembl chr 1:246,566,444...246,668,595 		JBrowse link
G CNTN3 contactin 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN3 mRNA CTD PMID:25607892 NCBI chr 3:74,262,568...74,614,659
Ensembl chr 3:74,262,568...74,614,659 		JBrowse link
G CNTN4 contactin 4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN4 mRNA CTD PMID:25607892 NCBI chr 3:2,098,866...3,057,959
Ensembl chr 3:2,098,813...3,057,959 		JBrowse link
G COL1A1 collagen type I alpha 1 chain increases degradation ISO enzacamene results in increased degradation of COL1A1 protein CTD PMID:15979666 NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632 		JBrowse link
G COPS2 COP9 signalosome subunit 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of COPS2 mRNA CTD PMID:25607892 NCBI chr15:49,122,727...49,155,599
Ensembl chr15:49,106,068...49,155,661 		JBrowse link
G CRH corticotropin releasing hormone multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] affects the expression of CRH mRNA CTD PMID:34383603 NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464 		JBrowse link
G CX3CL1 C-X3-C motif chemokine ligand 1 increases expression EXP enzacamene results in increased expression of CX3CL1 mRNA CTD PMID:30597193 NCBI chr16:57,372,490...57,385,044
Ensembl chr16:57,372,477...57,385,044 		JBrowse link
G CYP11B1 cytochrome P450 family 11 subfamily B member 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CYP11B1 mRNA CTD PMID:25607892 NCBI chr 8:142,872,357...142,879,825
Ensembl chr 8:142,872,356...142,879,846 		JBrowse link
G CYP17A1 cytochrome P450 family 17 subfamily A member 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CYP17A1 mRNA CTD PMID:25607892 NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472 		JBrowse link
G CYP19A1 cytochrome P450 family 19 subfamily A member 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CYP19A1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CYP19A1 mRNA CTD PMID:25607892 NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601 		JBrowse link
G DCC DCC netrin 1 receptor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DCC mRNA CTD PMID:25607892 NCBI chr18:52,340,197...53,535,899
Ensembl chr18:52,340,197...53,535,899 		JBrowse link
G DLG1 discs large MAGUK scaffold protein 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLG1 mRNA CTD PMID:25607892 NCBI chr 3:197,042,560...197,299,321
Ensembl chr 3:197,042,560...197,299,330 		JBrowse link
G DLG4 discs large MAGUK scaffold protein 4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DLG4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLG4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of DLG4 mRNA CTD PMID:25607892 NCBI chr17:7,187,187...7,220,050
Ensembl chr17:7,187,187...7,219,841 		JBrowse link
G DLGAP3 DLG associated protein 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of DLGAP3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLGAP3 mRNA CTD PMID:25607892 NCBI chr 1:34,865,436...34,929,650
Ensembl chr 1:34,865,436...34,929,650 		JBrowse link
G DNM1 dynamin 1 multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of DNM1 mRNA CTD PMID:34383603 NCBI chr 9:128,203,379...128,255,244
Ensembl chr 9:128,191,655...128,255,248 		JBrowse link
G DNMT3A DNA methyltransferase 3 alpha multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DNMT3A mRNA CTD PMID:25607892 NCBI chr 2:25,227,874...25,342,590
Ensembl chr 2:25,227,855...25,342,590 		JBrowse link
G DPP6 dipeptidyl peptidase like 6 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of DPP6 mRNA CTD PMID:25607892 NCBI chr 7:153,748,133...154,894,285
Ensembl chr 7:153,748,133...154,894,285 		JBrowse link
G EGF epidermal growth factor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of EGF mRNA CTD PMID:25607892 NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766 		JBrowse link
G EPHB4 EPH receptor B4 multiple interactions
increases expression		 EXP [EPHB4 mRNA affects the susceptibility to enzacamene] which results in increased expression of ZNF3 mRNA; EPHB4 mRNA promotes the reaction [enzacamene results in increased expression of SRRT mRNA]
enzacamene results in increased expression of EPHB4 mRNA		 CTD PMID:30597193 NCBI chr 7:100,802,565...100,827,523
Ensembl chr 7:100,802,565...100,827,523 		JBrowse link
G ERBB2 erb-b2 receptor tyrosine kinase 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA CTD PMID:25607892 NCBI chr17:39,688,094...39,728,658
Ensembl chr17:39,687,914...39,730,426 		JBrowse link
G ERBB3 erb-b2 receptor tyrosine kinase 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA CTD PMID:25607892 NCBI chr12:56,080,108...56,103,505
Ensembl chr12:56,076,799...56,103,505 		JBrowse link
G ERBB4 erb-b2 receptor tyrosine kinase 4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of ERBB4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of ERBB4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB4 mRNA CTD PMID:25607892 NCBI chr 2:211,375,717...212,538,802
Ensembl chr 2:211,375,717...212,538,841 		JBrowse link
G ESR1 estrogen receptor 1 increases activity
multiple interactions
decreases expression		 EXP
ISO		 enzacamene results in increased activity of ESR1 protein
[Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of ESR1 mRNA
enzacamene results in decreased expression of ESR1 mRNA
enzacamene binds to and results in increased activity of ESR1 protein		 CTD PMID:12765243 PMID:16079615 PMID:19150460 PMID:24004914 PMID:34383603 NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619 		JBrowse link
G ESR2 estrogen receptor 2 multiple interactions
increases activity
affects binding		 EXP
ISO		 enzacamene binds to and results in increased activity of ESR2 protein
[bisphenol A co-treated with Zearalenone co-treated with Arsenic co-treated with enzacamene co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [bisphenol A co-treated with Zearalenone co-treated with Arsenic co-treated with enzacamene] results in increased expression of ESR2 mRNA; [enzacamene co-treated with Estradiol co-treated with Triiodothyronine] affects the expression of ESR2 mRNA
enzacamene results in increased activity of ESR2 protein
enzacamene binds to ESR2 protein		 CTD PMID:12765243 PMID:15147785 PMID:16079615 PMID:27338438 NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112 		JBrowse link
G FGFR1 fibroblast growth factor receptor 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR1 mRNA CTD PMID:25607892 NCBI chr 8:38,411,143...38,468,635
Ensembl chr 8:38,400,215...38,468,834 		JBrowse link
G FGFR2 fibroblast growth factor receptor 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR2 mRNA CTD PMID:25607892 NCBI chr10:121,478,330...121,598,458
Ensembl chr10:121,478,332...121,598,458 		JBrowse link
G FYN FYN proto-oncogene, Src family tyrosine kinase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of FYN mRNA CTD PMID:25607892 NCBI chr 6:111,660,332...111,873,452
Ensembl chr 6:111,660,332...111,873,452 		JBrowse link
G GABRA4 gamma-aminobutyric acid type A receptor subunit alpha4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GABRA4 mRNA CTD PMID:25607892 NCBI chr 4:46,918,900...46,993,581
Ensembl chr 4:46,918,900...46,993,581 		JBrowse link
G GABRB1 gamma-aminobutyric acid type A receptor subunit beta1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GABRB1 mRNA CTD PMID:25607892 NCBI chr 4:46,993,647...47,426,447
Ensembl chr 4:46,993,723...47,426,447 		JBrowse link
G GLS glutaminase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GLS mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GLS mRNA CTD PMID:25607892 NCBI chr 2:190,880,821...190,965,552
Ensembl chr 2:190,880,821...190,965,552 		JBrowse link
G GRIA2 glutamate ionotropic receptor AMPA type subunit 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA CTD PMID:25607892 NCBI chr 4:157,220,120...157,366,075
Ensembl chr 4:157,204,182...157,387,146 		JBrowse link
G GRIA4 glutamate ionotropic receptor AMPA type subunit 4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIA4 mRNA CTD PMID:25607892 NCBI chr11:105,609,616...105,982,090
Ensembl chr11:105,609,535...105,982,090 		JBrowse link
G GRID2 glutamate ionotropic receptor delta type subunit 2 multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of GRID2 mRNA CTD PMID:34383603 NCBI chr 4:92,303,966...93,810,456
Ensembl chr 4:92,303,966...93,810,157 		JBrowse link
G GRIK2 glutamate ionotropic receptor kainate type subunit 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIK2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK2 mRNA CTD PMID:25607892 NCBI chr 6:101,393,708...102,070,083
Ensembl chr 6:100,962,701...102,081,622 		JBrowse link
G GRIK4 glutamate ionotropic receptor kainate type subunit 4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIK4 mRNA CTD PMID:25607892 NCBI chr11:120,511,748...120,988,906
Ensembl chr11:120,511,746...120,988,906 		JBrowse link
G GRIK5 glutamate ionotropic receptor kainate type subunit 5 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK5 mRNA CTD PMID:25607892 NCBI chr19:41,998,324...42,070,206
Ensembl chr19:41,998,321...42,070,206 		JBrowse link
G GRIN1 glutamate ionotropic receptor NMDA type subunit 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of GRIN1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN1 mRNA CTD PMID:25607892 NCBI chr 9:137,139,154...137,168,756
Ensembl chr 9:137,138,346...137,168,756 		JBrowse link
G GRIN2B glutamate ionotropic receptor NMDA type subunit 2B multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN2B mRNA CTD PMID:25607892 NCBI chr12:13,537,337...13,982,134
Ensembl chr12:13,437,942...13,982,002 		JBrowse link
G GRIN2C glutamate ionotropic receptor NMDA type subunit 2C multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN2C mRNA CTD PMID:25607892 NCBI chr17:74,842,023...74,861,532
Ensembl chr17:74,842,023...74,861,504 		JBrowse link
G GRIN2D glutamate ionotropic receptor NMDA type subunit 2D multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN2D mRNA; [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA CTD PMID:25607892 PMID:34383603 NCBI chr19:48,393,668...48,444,931
Ensembl chr19:48,393,668...48,444,931 		JBrowse link
G GRIN3A glutamate ionotropic receptor NMDA type subunit 3A multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN3A mRNA CTD PMID:25607892 NCBI chr 9:101,569,352...101,738,647
Ensembl chr 9:101,569,352...101,738,647 		JBrowse link
G GRIP1 glutamate receptor interacting protein 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIP1 mRNA CTD PMID:25607892 NCBI chr12:66,347,431...67,069,338
Ensembl chr12:66,347,431...67,069,162 		JBrowse link
G GSK3B glycogen synthase kinase 3 beta increases phosphorylation EXP enzacamene results in increased phosphorylation of GSK3B protein CTD PMID:30597193 NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994 		JBrowse link
G HES6 hes family bHLH transcription factor 6 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of HES6 mRNA CTD PMID:25607892 NCBI chr 2:238,238,267...238,240,038
Ensembl chr 2:238,238,267...238,240,662 		JBrowse link
G HR HR lysine demethylase and nuclear receptor corepressor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of HR mRNA CTD PMID:25607892 NCBI chr 8:22,114,419...22,131,052
Ensembl chr 8:22,114,419...22,133,384 		JBrowse link
G HSD17B10 hydroxysteroid 17-beta dehydrogenase 10 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of HSD17B10 mRNA CTD PMID:25607892 NCBI chr  X:53,431,258...53,434,376
Ensembl chr  X:53,431,258...53,434,370 		JBrowse link
G HSD17B8 hydroxysteroid 17-beta dehydrogenase 8 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of HSD17B8 mRNA CTD PMID:25607892 NCBI chr 6:33,204,655...33,206,831
Ensembl chr 6:33,204,655...33,206,831 		JBrowse link
G ID2 inhibitor of DNA binding 2 decreases expression EXP enzacamene results in decreased expression of ID2 mRNA CTD PMID:23397585 NCBI chr 2:8,682,056...8,684,461
Ensembl chr 2:8,678,845...8,684,461 		JBrowse link
G IGF1R insulin like growth factor 1 receptor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of IGF1R mRNA CTD PMID:25607892 NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530 		JBrowse link
G IGF2R insulin like growth factor 2 receptor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of IGF2R mRNA CTD PMID:25607892 NCBI chr 6:159,969,082...160,111,504
Ensembl chr 6:159,969,082...160,113,507 		JBrowse link
G IL1RAPL1 interleukin 1 receptor accessory protein like 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of IL1RAPL1 mRNA CTD PMID:25607892 NCBI chr  X:28,587,446...29,956,718
Ensembl chr  X:28,587,446...29,956,718 		JBrowse link
G ITGB5 integrin subunit beta 5 decreases expression
increases expression		 EXP enzacamene results in decreased expression of ITGB5 mRNA
enzacamene results in increased expression of ITGB5 mRNA		 CTD PMID:23397585 PMID:30597193 NCBI chr 3:124,761,948...124,901,418
Ensembl chr 3:124,761,948...124,901,418 		JBrowse link
G JAG1 jagged canonical Notch ligand 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of JAG1 mRNA CTD PMID:25607892 NCBI chr20:10,637,684...10,673,999
Ensembl chr20:10,637,684...10,673,999 		JBrowse link
G KISS1 KiSS-1 metastasis suppressor multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of KISS1 mRNA CTD PMID:34383603 NCBI chr 1:204,190,341...204,196,491
Ensembl chr 1:204,190,341...204,196,491 		JBrowse link
G LIN7A lin-7 homolog A, crumbs cell polarity complex component multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of LIN7A mRNA CTD PMID:25607892 NCBI chr12:80,792,520...80,937,934
Ensembl chr12:80,792,520...80,937,934 		JBrowse link
G MAGI2 membrane associated guanylate kinase, WW and PDZ domain containing 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of MAGI2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MAGI2 mRNA CTD PMID:25607892 NCBI chr 7:78,017,055...79,453,667
Ensembl chr 7:78,017,055...79,453,667 		JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases phosphorylation EXP enzacamene results in increased phosphorylation of MAPK1 protein CTD PMID:30597193 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680 		JBrowse link
G MAPK3 mitogen-activated protein kinase 3 increases phosphorylation EXP enzacamene results in increased phosphorylation of MAPK3 protein CTD PMID:30597193 NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506 		JBrowse link
G MDGA2 MAM domain containing glycosylphosphatidylinositol anchor 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of MDGA2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MDGA2 mRNA CTD PMID:25607892 NCBI chr14:46,839,623...47,675,605
Ensembl chr14:46,840,092...47,675,605 		JBrowse link
G MET MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MET mRNA CTD PMID:25607892 NCBI chr 7:116,672,196...116,798,377
Ensembl chr 7:116,672,196...116,798,377 		JBrowse link
G MMP3 matrix metallopeptidase 3 multiple interactions ISO [enzacamene co-treated with octylmethoxycinnamate co-treated with bisphenol A co-treated with butylparaben] results in increased expression of MMP3 mRNA CTD PMID:25305543 NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609 		JBrowse link
G NCOA1 nuclear receptor coactivator 1 increases expression ISO enzacamene results in increased expression of NCOA1 mRNA CTD PMID:19150460 NCBI chr 2:24,491,254...24,770,702
Ensembl chr 2:24,491,254...24,770,702 		JBrowse link
G NF1 neurofibromin 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NF1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NF1 mRNA CTD PMID:25607892 NCBI chr17:31,094,927...31,377,677
Ensembl chr17:31,094,927...31,382,116 		JBrowse link
G NLGN1 neuroligin 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NLGN1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NLGN1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NLGN1 mRNA CTD PMID:25607892 NCBI chr 3:173,395,952...174,294,372
Ensembl chr 3:173,396,284...174,294,372 		JBrowse link
G NOTCH2 notch receptor 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NOTCH2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NOTCH2 mRNA CTD PMID:25607892 NCBI chr 1:119,911,553...120,069,662
Ensembl chr 1:119,911,553...120,100,779 		JBrowse link
G NOTCH4 notch receptor 4 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NOTCH4 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NOTCH4 mRNA CTD PMID:25607892 NCBI chr 6:32,194,843...32,224,067
Ensembl chr 6:32,194,843...32,224,067 		JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 increases activity EXP enzacamene results in increased activity of NR1I3 protein CTD PMID:28927721 NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244 		JBrowse link
G NR3C1 nuclear receptor subfamily 3 group C member 1 multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of NR3C1 mRNA CTD PMID:34383603 NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512 		JBrowse link
G NR3C2 nuclear receptor subfamily 3 group C member 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NR3C2 mRNA CTD PMID:25607892 NCBI chr 4:148,078,764...148,445,508
Ensembl chr 4:148,078,762...148,444,698 		JBrowse link
G NRCAM neuronal cell adhesion molecule multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRCAM mRNA CTD PMID:25607892 NCBI chr 7:108,147,649...108,456,720
Ensembl chr 7:108,147,623...108,456,717 		JBrowse link
G NRG1 neuregulin 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NRG1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NRG1 mRNA CTD PMID:25607892 NCBI chr 8:31,639,245...32,774,046
Ensembl chr 8:31,639,222...32,855,666 		JBrowse link
G NRP1 neuropilin 1 increases expression EXP enzacamene results in increased expression of NRP1 mRNA CTD PMID:30597193 NCBI chr10:33,177,493...33,334,667
Ensembl chr10:33,177,492...33,336,262 		JBrowse link
G NRXN1 neurexin 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRXN1 mRNA CTD PMID:25607892 NCBI chr 2:49,918,503...51,032,132
Ensembl chr 2:49,918,503...51,225,575 		JBrowse link
G NRXN2 neurexin 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRXN2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NRXN2 mRNA CTD PMID:25607892 NCBI chr11:64,606,174...64,723,197
Ensembl chr11:64,606,174...64,723,197 		JBrowse link
G NTRK1 neurotrophic receptor tyrosine kinase 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NTRK1 mRNA CTD PMID:25607892 NCBI chr 1:156,815,750...156,881,850
Ensembl chr 1:156,815,636...156,881,850 		JBrowse link
G NTRK2 neurotrophic receptor tyrosine kinase 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NTRK2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NTRK2 mRNA CTD PMID:25607892 NCBI chr 9:84,668,522...85,027,054
Ensembl chr 9:84,668,375...85,095,751 		JBrowse link
G NTRK3 neurotrophic receptor tyrosine kinase 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NTRK3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NTRK3 mRNA CTD PMID:25607892 NCBI chr15:87,859,751...88,256,739
Ensembl chr15:87,859,751...88,256,791 		JBrowse link
G NXPH3 neurexophilin 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NXPH3 mRNA CTD PMID:25607892 NCBI chr17:49,575,871...49,583,827
Ensembl chr17:49,575,871...49,583,827 		JBrowse link
G OXT oxytocin/neurophysin I prepropeptide multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of OXT mRNA CTD PMID:34383603 NCBI chr20:3,071,620...3,072,517
Ensembl chr20:3,071,620...3,072,517 		JBrowse link
G PCNA proliferating cell nuclear antigen decreases expression EXP enzacamene results in decreased expression of PCNA mRNA CTD PMID:30597193 NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626 		JBrowse link
G PGR progesterone receptor multiple interactions
affects expression		 EXP
ISO		 enzacamene binds to and results in decreased activity of PGR protein
enzacamene affects the expression of PGR mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PGR mRNA		 CTD PMID:15537743 PMID:19150460 PMID:25607892 NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813 		JBrowse link
G POMC proopiomelanocortin multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] affects the expression of POMC mRNA CTD PMID:34383603 NCBI chr 2:25,160,860...25,168,580
Ensembl chr 2:25,160,853...25,168,903 		JBrowse link
G PPP1R1B protein phosphatase 1 regulatory inhibitor subunit 1B multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of PPP1R1B mRNA CTD PMID:34383603 NCBI chr17:39,626,707...39,636,624
Ensembl chr17:39,626,740...39,636,626 		JBrowse link
G PRKN parkin RBR E3 ubiquitin protein ligase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PRKN mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of PRKN mRNA CTD PMID:25607892 NCBI chr 6:161,347,417...162,727,766
Ensembl chr 6:161,347,417...162,727,775 		JBrowse link
G RELN reelin multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of RELN mRNA CTD PMID:25607892 NCBI chr 7:103,471,789...103,989,658
Ensembl chr 7:103,471,381...103,989,658 		JBrowse link
G ROBO1 roundabout guidance receptor 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ROBO1 mRNA CTD PMID:25607892 NCBI chr 3:78,597,239...79,767,998
Ensembl chr 3:78,597,239...79,767,998 		JBrowse link
G RPS6 ribosomal protein S6 increases phosphorylation EXP enzacamene results in increased phosphorylation of RPS6 protein CTD PMID:30597193 NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236 		JBrowse link
G RPS6KA1 ribosomal protein S6 kinase A1 increases phosphorylation EXP enzacamene results in increased phosphorylation of RPS6KA1 protein CTD PMID:30597193 NCBI chr 1:26,529,761...26,575,025
Ensembl chr 1:26,529,761...26,575,030 		JBrowse link
G RPS6KB1 ribosomal protein S6 kinase B1 increases phosphorylation EXP enzacamene results in increased phosphorylation of RPS6KB1 protein CTD PMID:30597193 NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574 		JBrowse link
G SEMA6A semaphorin 6A increases expression EXP enzacamene results in increased expression of SEMA6A mRNA CTD PMID:30597193 NCBI chr 5:116,443,555...116,574,823
Ensembl chr 5:116,443,555...116,574,823 		JBrowse link
G SHANK1 SH3 and multiple ankyrin repeat domains 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SHANK1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK1 mRNA CTD PMID:25607892 NCBI chr19:50,659,255...50,719,802
Ensembl chr19:50,659,255...50,719,802 		JBrowse link
G SHANK2 SH3 and multiple ankyrin repeat domains 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SHANK2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SHANK2 mRNA CTD PMID:25607892 NCBI chr11:70,467,854...71,253,228
Ensembl chr11:70,467,854...71,252,577 		JBrowse link
G SHANK3 SH3 and multiple ankyrin repeat domains 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK3 mRNA CTD PMID:25607892 NCBI chr22:50,672,823...50,733,212
Ensembl chr22:50,674,415...50,733,212 		JBrowse link
G SLC17A7 solute carrier family 17 member 7 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC17A7 mRNA CTD PMID:25607892 NCBI chr19:49,429,401...49,441,527
Ensembl chr19:49,429,401...49,442,360 		JBrowse link
G SLC1A1 solute carrier family 1 member 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A1 mRNA CTD PMID:25607892 NCBI chr 9:4,490,468...4,587,469
Ensembl chr 9:4,490,468...4,587,469 		JBrowse link
G SLC1A2 solute carrier family 1 member 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLC1A2 mRNA CTD PMID:25607892 NCBI chr11:35,251,205...35,420,507
Ensembl chr11:35,251,205...35,420,063 		JBrowse link
G SLC1A3 solute carrier family 1 member 3 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A3 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLC1A3 mRNA CTD PMID:25607892 NCBI chr 5:36,606,606...36,688,334
Ensembl chr 5:36,596,588...36,688,334 		JBrowse link
G SLC1A6 solute carrier family 1 member 6 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A6 mRNA CTD PMID:25607892 NCBI chr19:14,950,033...15,010,643
Ensembl chr19:14,950,033...15,022,990 		JBrowse link
G SLIT1 slit guidance ligand 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SLIT1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLIT1 mRNA CTD PMID:25607892 NCBI chr10:96,998,038...97,185,959
Ensembl chr10:96,998,038...97,185,959 		JBrowse link
G SPTBN2 spectrin beta, non-erythrocytic 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SPTBN2 mRNA CTD PMID:25607892 NCBI chr11:66,682,497...66,744,682
Ensembl chr11:66,682,497...66,744,670 		JBrowse link
G SRRT serrate, RNA effector molecule multiple interactions
increases expression		 EXP EPHB4 mRNA promotes the reaction [enzacamene results in increased expression of SRRT mRNA] CTD PMID:30597193 NCBI chr 7:100,875,103...100,888,664
Ensembl chr 7:100,875,103...100,888,664 		JBrowse link
G STMN2 stathmin 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STMN2 mRNA CTD PMID:25607892 NCBI chr 8:79,611,117...79,666,158
Ensembl chr 8:79,611,117...79,666,158 		JBrowse link
G STS steroid sulfatase multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of STS mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of STS mRNA CTD PMID:25607892 NCBI chr  X:7,147,290...7,354,641
Ensembl chr  X:7,147,237...7,804,358 		JBrowse link
G STX1B syntaxin 1B multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STX1B mRNA CTD PMID:25607892 NCBI chr16:30,989,256...31,010,638
Ensembl chr16:30,989,256...31,010,638 		JBrowse link
G STXBP1 syntaxin binding protein 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of STXBP1 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STXBP1 mRNA CTD PMID:25607892 NCBI chr 9:127,611,912...127,696,029
Ensembl chr 9:127,579,370...127,696,027 		JBrowse link
G SYNGAP1 synaptic Ras GTPase activating protein 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SYNGAP1 mRNA CTD PMID:25607892 NCBI chr 6:33,418,167...33,453,689
Ensembl chr 6:33,419,661...33,453,689 		JBrowse link
G SYP synaptophysin multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SYP mRNA CTD PMID:25607892 NCBI chr  X:49,187,815...49,200,193
Ensembl chr  X:49,187,815...49,200,218 		JBrowse link
G SYT6 synaptotagmin 6 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SYT6 mRNA CTD PMID:25607892 NCBI chr 1:114,089,292...114,153,869
Ensembl chr 1:114,089,291...114,153,880 		JBrowse link
G TBX3 T-box transcription factor 3 increases expression EXP enzacamene results in increased expression of TBX3 mRNA CTD PMID:23397585 NCBI chr12:114,670,255...114,684,175
Ensembl chr12:114,670,255...114,684,175 		JBrowse link
G TFF1 trefoil factor 1 increases expression
multiple interactions		 EXP enzacamene results in increased expression of TFF1 mRNA
[oxybenzone co-treated with 2,4-dihydroxybenzophenone co-treated with octylmethoxycinnamate co-treated with enzacamene] results in increased expression of TFF1 mRNA		 CTD PMID:16183391 NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535 		JBrowse link
G TGFB1 transforming growth factor beta 1 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of TGFB1 mRNA CTD PMID:25607892 NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922 		JBrowse link
G TGM2 transglutaminase 2 multiple interactions
decreases expression		 EXP ADGRG1 mRNA inhibits the reaction [enzacamene results in decreased expression of TGM2 mRNA] CTD PMID:30597193 NCBI chr20:38,127,385...38,168,475
Ensembl chr20:38,127,385...38,166,578 		JBrowse link
G TGOLN2 trans-golgi network protein 2 increases expression EXP enzacamene results in increased expression of TGOLN2 mRNA CTD PMID:23397585 NCBI chr 2:85,318,027...85,327,989
Ensembl chr 2:85,318,027...85,328,251 		JBrowse link
G TH tyrosine hydroxylase multiple interactions ISO [Plasticizers co-treated with Fungicides, Industrial co-treated with Linuron co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with Dichlorodiphenyl Dichloroethylene co-treated with butylparaben co-treated with Acetaminophen] results in decreased expression of TH mRNA CTD PMID:34383603 NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815 		JBrowse link
G TSC2 TSC complex subunit 2 multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of TSC2 mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of TSC2 mRNA CTD PMID:25607892 NCBI chr16:2,047,985...2,089,491
Ensembl chr16:2,047,967...2,089,491 		JBrowse link
G TSNAX translin associated factor X multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of TSNAX mRNA CTD PMID:25607892 NCBI chr 1:231,528,669...231,566,524
Ensembl chr 1:231,528,541...231,566,524 		JBrowse link
G UNC5A unc-5 netrin receptor A multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of UNC5A mRNA CTD PMID:25607892 NCBI chr 5:176,810,559...176,880,898
Ensembl chr 5:176,810,519...176,880,898 		JBrowse link
G UNC5B unc-5 netrin receptor B multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of UNC5B mRNA CTD PMID:25607892 NCBI chr10:71,212,570...71,302,864
Ensembl chr10:71,212,570...71,302,864 		JBrowse link
G UNC5C unc-5 netrin receptor C multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of UNC5C mRNA; [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of UNC5C mRNA CTD PMID:25607892 NCBI chr 4:95,162,504...95,548,973
Ensembl chr 4:95,162,504...95,549,206 		JBrowse link
G VEGFA vascular endothelial growth factor A multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of VEGFA mRNA CTD PMID:25607892 NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487 		JBrowse link
G VLDLR very low density lipoprotein receptor multiple interactions ISO [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of VLDLR mRNA CTD PMID:25607892 NCBI chr 9:2,621,787...2,660,056
Ensembl chr 9:2,621,182...2,660,056 		JBrowse link
G ZNF3 zinc finger protein 3 multiple interactions EXP [EPHB4 mRNA affects the susceptibility to enzacamene] which results in increased expression of ZNF3 mRNA CTD PMID:30597193 NCBI chr 7:100,063,837...100,082,577
Ensembl chr 7:100,064,033...100,082,548 		JBrowse link
G ZNF676 zinc finger protein 676 decreases expression EXP enzacamene results in decreased expression of ZNF676 mRNA CTD PMID:23397585 NCBI chr19:22,179,089...22,260,304
Ensembl chr19:22,179,089...22,215,801 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 26041
    chemical entity 26020
      atom 26016
        nonmetal atom 25505
          carbon atom 25399
            organic molecular entity 25399
              isoprenoid 14677
                terpenoid 14315
                  monoterpenoid 2078
                    enzacamene 157
Path 2
Term Annotations click to browse term
  CHEBI ontology 26041
    subatomic particle 26016
      composite particle 26016
        hadron 26016
          baryon 26016
            nucleon 26016
              atomic nucleus 26016
                atom 26016
                  main group element atom 25841
                    main group molecular entity 25841
                      s-block molecular entity 25162
                        hydrogen molecular entity 24761
                          hydrides 22973
                            organic hydride 21936
                              organic fundamental parent 21936
                                hydrocarbon 21359
                                  terpene 14677
                                    monoterpene 3949
                                      monoterpenoid 2078
                                        enzacamene 157
paths to the root